Phase IB/II Study of Pasireotide, Everolimus and Selective Internal Radioembolization Therapy (SIRT) for Unresectable Neuroendocrine Hepatic Metastases
Active, no longer recruiting
Phase of Trial: Phase I/II
Latest Information Update: 21 Nov 2016
At a glance
- Drugs Everolimus (Primary) ; Pasireotide (Primary) ; Yttrium-90
- Indications Intestinal cancer; Liver metastases; Neuroendocrine tumours; Pancreatic cancer
- Focus Adverse reactions
- 17 Nov 2016 Planned End Date changed from 1 Mar 2017 to 1 Mar 2018.
- 17 Nov 2016 Planned primary completion date changed from 1 Dec 2016 to 1 Dec 2017.
- 13 Nov 2015 Planned End Date changed from 1 Mar 2016 to 1 Mar 2017 as reported by ClinicalTrials.gov record.